Enhanced antitumor efficacy of combined targeting of adenosine A2B receptor and PD-1 is mediated via multiple effects on different cell populations within tumor microenvironment | Synapse
March 2, 2026Open Access
Enhanced antitumor efficacy of combined targeting of adenosine A2B receptor and PD-1 is mediated via multiple effects on different cell populations within tumor microenvironment
Puntos clave
The study aims to explore how inhibiting the adenosine A2B receptor affects immune responses in tumors.
Examined the effects of A2B receptor inhibition on TGFβ signaling.
Assessed the impact of combining A2B receptor blockade with immune checkpoint inhibitors.
Utilized a model of non-small cell lung cancer for analysis.
Blocking the A2B receptor reduced TGFβ signaling levels.
Inhibition enhanced the efficacy of immune checkpoint inhibitor therapy.
Observed changes in various immune cell populations within the tumor microenvironment.
Resumen
Our findings suggest that inhibition of adenosine activity by blocking the A2B receptor reduces TGFβ signaling and enhances the efficacy of ICI therapy in NSCLC.